西藏诺迪康药业股份有限公司2025年度差异化分红法律意见书详解
一、报告要点概览
- 差异化分红方案已获董事会和股东会审议通过，涉及将回购专用证券账户股份排除在利润分配之外。
- 2025年度现金分红总额为562,810,776.57元，其中已发放2025年半年度分红283,963,211.68元，本次将派发现金红利278,847,564.89元（含税）。
- 每股现金红利为0.876元（含税），以实施权益分派股权登记日的总股本扣除回购股份为基数。
- 根据回购方案，公司已通过集中竞价方式回购4,000,058股，占总股本1.24%，这些股份不参与利润分配。
- 法律意见书明确此分红方案符合《公司法》、《证券法》及相关监管规定。
- 差异化分红对除权除息参考价格影响极小，仅为0.03%，对股价波动影响有限，但反映公司严格依法合规操作。
二、对投资者和股东的重要影响与关注事项
- 回购股份不参与利润分配： 投资者需注意，公司回购专用账户中的4,000,058股A股将不会参与此次现金分红。这意味着实际参与分红的股份为318,319,138股，分红基数略低于总股本。
- 分红总额不变，每股红利金额将动态调整： 若在权益分派登记日前发生可转债转股、股权激励授予股份回购注销等事项，总股本发生变化，公司将维持分红总额不变，相应调整每股分红金额。投资者应关注相关公告，避免权益受影响。
- 除权除息价格影响极小： 差异化分红对除权除息参考价格的影响绝对值仅为0.03%，远低于1%的警戒线，对短期股价影响有限，但显示公司分红政策稳健、合规。
- 法律合规风险极低： 法律意见书确认本次差异化分红不存在损害公司及股东利益的情形，符合所有相关法律法规与公司章程要求，说明公司治理合规性强，有助于提升市场信心。
- 后续潜在影响： 若公司继续进行股份回购或实施股权激励计划，未来分红方案仍可能出现差异化分配情形。建议投资者持续关注公司公告和分红政策动态。
三、分红方案详细数据
- 总股本：322,319,196股
- 回购专用证券账户股份：4,000,058股
- 实际参与分红股份：318,319,138股
- 2025年度现金分红总额：562,810,776.57元
- 已发放半年度现金分红：283,963,211.68元
- 本次拟派发现金红利：278,847,564.89元（含税）
- 每股拟派发现金：0.876元（含税）
- 除权除息参考价格将微调，变化幅度不足0.03%
四、投资者需密切关注事项
- 分红基准日与股权登记日变动，及回购股份数量变化对未来分红的影响。
- 公司后续是否继续实施股份回购或股权激励计划，可能影响未来分红方案。
- 本次差异化分红方案已充分披露，短期内对公司股价影响有限，但中长期有利于公司合规治理形象。
五、结论
本次差异化分红方案展现了西藏诺迪康药业股份有限公司依法合规、以股东利益为重的公司治理风格。尽管对短期股价影响有限，但公司资本运作透明、分红政策稳定，长期来看有望提升市场信心和公司估值。建议投资者持续关注公司后续公告和业务动态。
免责声明：本报道根据公开法律意见书整理，仅供投资者参考，不构成任何投资建议。投资者据此操作，风险自担。
English Version
Detailed Analysis: Tibet Rhodiola Pharmaceutical Co., Ltd. 2025 Differentiated Dividend Legal Opinion
1. Key Highlights
- Differentiated dividend scheme approved by the Board and Shareholders, excluding repurchased shares from the profit distribution.
- Total 2025 cash dividend: RMB 562,810,776.57, of which RMB 283,963,211.68 has already been paid as interim dividend. The current round will pay out RMB 278,847,564.89 (tax included).
- Cash dividend per share: RMB 0.876 (tax included), calculated on the total shares minus shares in the repurchase account as of the record date.
- Company repurchased 4,000,058 A-shares (1.24% of total shares) via centralized bidding; these shares will not participate in the dividend.
- The legal opinion confirms that the scheme complies with the Company Law, Securities Law, and regulatory requirements.
- The differentiated dividend has only a minimal effect on the reference price for ex-dividend, with a difference of just 0.03%—showing little immediate price impact but strong compliance.
2. Important Points for Investors and Shareholders
- Repurchased shares excluded from dividend: The 4,000,058 A-shares held in the special repurchase account will not participate in this cash dividend, meaning the actual eligible shares are 318,319,138, slightly less than total shares.
- Total dividend unchanged, per-share payout may adjust: If there are changes to share capital (e.g., CB conversion, share incentive cancellations) before the record date, the company will keep the total payout unchanged but will adjust per-share amounts. Investors should watch for related company announcements.
- Minimal impact on ex-dividend price: The impact of this differentiated dividend on the ex-dividend reference price is only 0.03%, well below the 1% threshold, so short-term price effect is negligible. However, this demonstrates prudent and compliant dividend policy.
- Low legal/compliance risk: The legal opinion confirms this scheme does not harm company or shareholder interests and fully complies with all company regulations, bolstering market confidence.
- Potential ongoing effects: If the company continues share buybacks or incentive plans, future dividends may also be differentiated. Investors should monitor company updates.
3. Dividend Scheme Details
- Total shares: 322,319,196
- Repurchased shares: 4,000,058
- Shares eligible for dividend: 318,319,138
- Total 2025 cash dividend: RMB 562,810,776.57
- Interim dividend already paid: RMB 283,963,211.68
- Current dividend payout: RMB 278,847,564.89 (tax included)
- Cash dividend per share: RMB 0.876 (tax included)
- Ex-dividend reference price adjustment is less than 0.03%
4. Key Issues for Investors to Monitor
- Changes in record dates and share capital affecting future dividend schemes.
- Continued share buybacks or incentive plans may result in further differentiated dividends.
- This differentiated dividend scheme is fully disclosed; near-term price impact is limited, but long-term transparency and stable payout policy may support the share price.
5. Conclusion
Tibet Rhodiola Pharmaceutical’s differentiated dividend plan demonstrates strong legal compliance and shareholder focus. While the short-term share price impact is minimal, the company’s transparent and stable dividend policy can support long-term market confidence and valuation. Investors are advised to follow future company disclosures and developments closely.
Disclaimer: This report is based on the published legal opinion and is for reference only. It does not constitute investment advice. Investors should operate at their own risk.
